Home LiteratureArticle Details
PMID: 11245282 Published · ppublish English Journal Article Review

Molecular mechanisms of tumor angiogenesis and tumor progression.

Journal of neuro-oncology ·Vol. 50 ·No. 1-2 ·2000-00-00 ·Pages 63-70

Cavallaro U, Christofori G

Abstract

The formation of new blood vessels (angiogenesis) is crucial for the growth and persistence of primary solid tumors and their metastases. Furthermore, angiogenesis is also required for metastatic dissemination, since an increase in vascular density will allow easier access of tumor cells to the circulation. Induction of angiogenesis precedes the formation of malignant tumors, and increased vascularization seems to correlate with the invasive properties of tumors and thus with the malignant tumor phenotype. In the last few years, the discovery and characterization of tumor-derived angiogenesis modulators greatly contributed to our understanding of how tumors regulate angiogenesis. However, although angiogenesis appears to be a rate-limiting event in tumor growth and metastatic dissemination, a direct connection between the induction of angiogenesis and the progression to tumor malignancy is less well understood. In this review, we discuss the most recent observations concerning the modulation of angiogenesis and their implications in tumor progression, as well as their potential impact on cancer therapy.

MeSH Terms
Angiogenesis Inducing Agents/physiology Angiogenesis Inhibitors/pharmacology,therapeutic use Angiostatins Animals Collagen/physiology,therapeutic use Disease Progression Endostatins Endothelial Growth Factors/physiology Humans Lymphokines/physiology Neoplasm Invasiveness Neoplasm Metastasis Neoplasm Proteins/drug effects,physiology Neoplasms/blood supply Neoplasms, Experimental/drug therapy Neovascularization, Pathologic/physiopathology Peptide Fragments/physiology,therapeutic use Plasminogen/physiology,therapeutic use Receptor Protein-Tyrosine Kinases/drug effects,physiology Receptor, TIE-2 Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Chemicals
Angiogenesis Inducing Agents Angiogenesis Inhibitors Endostatins Endothelial Growth Factors Lymphokines Neoplasm Proteins Peptide Fragments Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors Angiostatins Plasminogen Collagen Receptor Protein-Tyrosine Kinases Receptor, TIE-2
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Cavallaro U
Research Institute of Molecular Pathology, Vienna, Austria.
Christofori G
References (77)
77 references, click to expand
  1. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.
    J Cell Biol. 1997 Aug 11;138(3):707-17 PMID: 9245797
  2. Angiostatin induces and sustains dormancy of human primary tumors in mice.
    Nat Med. 1996 Jun;2(6):689-92 PMID: 8640562
  3. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma.
    Hum Pathol. 1999 Apr;30(4):419-24 PMID: 10208463
  4. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase.
    J Cell Physiol. 1994 Jul;160(1):194-202 PMID: 7517405
  5. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2.
    Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8829-34 PMID: 9671764
  6. Endostatin induces endothelial cell apoptosis.
    J Biol Chem. 1999 Apr 23;274(17):11721-6 PMID: 10206987
  7. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth.
    Am J Pathol. 1985 Sep;120(3):327-32 PMID: 4037064
  8. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.
    Cell. 1991 Sep 20;66(6):1095-104 PMID: 1717155
  9. Tumor induction of VEGF promoter activity in stromal cells.
    Cell. 1998 Sep 18;94(6):715-25 PMID: 9753319
  10. Inhibitory effect of full-length human endostatin on in vitro angiogenesis.
    Biochem Biophys Res Commun. 1999 Sep 24;263(2):340-5 PMID: 10491294
  11. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma.
    Cancer Res. 1995 Dec 15;55(24):6071-6 PMID: 8521395
  12. The role of basement membranes in vascular development.
    Ann N Y Acad Sci. 1990;588:61-72 PMID: 2192650
  13. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation.
    J Cell Physiol. 1993 Nov;157(2):351-8 PMID: 7693724
  14. Clinical applications of angiogenic growth factors and their inhibitors.
    Nat Med. 1999 Dec;5(12):1359-64 PMID: 10581076
  15. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
    Cell. 1996 Aug 9;86(3):353-64 PMID: 8756718
  16. Angiogenesis in cancer, vascular, rheumatoid and other disease.
    Nat Med. 1995 Jan;1(1):27-31 PMID: 7584949
  17. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation.
    Nature. 1995 Jul 6;376(6535):70-4 PMID: 7596437
  18. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
    Cancer Res. 1992 Dec 1;52(23):6702-4 PMID: 1384969
  19. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding.
    Am J Pathol. 1999 Jul;155(1):71-6 PMID: 10393839
  20. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization.
    Am J Pathol. 1998 Sep;153(3):757-65 PMID: 9736026
  21. Multiple forms of angiostatin induce apoptosis in endothelial cells.
    Blood. 1998 Dec 15;92(12):4730-41 PMID: 9845539
  22. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.
    Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6 PMID: 9023347
  23. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice.
    Am J Pathol. 1999 Feb;154(2):581-90 PMID: 10027415
  24. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding.
    EMBO J. 1999 Aug 16;18(16):4414-23 PMID: 10449407
  25. The role of alphav integrins during angiogenesis.
    Mol Med. 1998 Dec;4(12):741-50 PMID: 9990860
  26. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
    EMBO J. 1999 Nov 15;18(22):6240-8 PMID: 10562536
  27. Mechanisms of angiogenesis.
    Nature. 1997 Apr 17;386(6626):671-4 PMID: 9109485
  28. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.
    Cold Spring Harb Symp Quant Biol. 1994;59:483-9 PMID: 7587102
  29. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis.
    Int J Dev Biol. 1998;42(7):995-1002 PMID: 9853830
  30. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.
    Nature. 1997 Nov 27;390(6658):404-7 PMID: 9389480
  31. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.
    Genes Dev. 1999 May 1;13(9):1055-66 PMID: 10323857
  32. Integrins and cancer.
    Curr Opin Cell Biol. 1996 Oct;8(5):724-30 PMID: 8939661
  33. The biology of vascular endothelial growth factor.
    Endocr Rev. 1997 Feb;18(1):4-25 PMID: 9034784
  34. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
    Cell. 1994 Oct 21;79(2):315-28 PMID: 7525077
  35. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2.
    Proc Natl Acad Sci U S A. 1998 May 12;95(10):5672-7 PMID: 9576942
  36. Signaling angiogenesis and lymphangiogenesis.
    Curr Opin Cell Biol. 1998 Apr;10(2):159-64 PMID: 9561839
  37. A cancer therapy resistant to resistance.
    Nature. 1997 Nov 27;390(6658):335-6 PMID: 9389468
  38. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.
    Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3609-14 PMID: 9520413
  39. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
    Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2002-7 PMID: 8700875
  40. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF).
    Biochem Biophys Res Commun. 1999 Jan 19;254(2):480-3 PMID: 9918864
  41. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis.
    J Cell Biol. 1998 Jun 29;141(7):1659-73 PMID: 9647657
  42. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
    Cell. 1997 Jan 24;88(2):277-85 PMID: 9008168
  43. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.
    Invest Ophthalmol Vis Sci. 1997 Apr;38(5):817-23 PMID: 9112976
  44. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
    Nature. 1992 Oct 29;359(6398):843-5 PMID: 1279431
  45. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.
    Cancer Res. 1993 Dec 1;53(23):5822-7 PMID: 7694795
  46. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.
    Science. 1997 Jul 4;277(5322):55-60 PMID: 9204896
  47. gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice.
    J Exp Med. 1995 Dec 1;182(6):2069-77 PMID: 7500052
  48. How tumors become angiogenic.
    Adv Cancer Res. 1996;69:135-74 PMID: 8791681
  49. Angiogenesis.
    J Biol Chem. 1992 Jun 5;267(16):10931-4 PMID: 1375931
  50. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD.
    Proc Natl Acad Sci U S A. 1998 May 12;95(10 ):5579-83 PMID: 9576925
  51. Zinc-binding of endostatin is essential for its antiangiogenic activity.
    Biochem Biophys Res Commun. 1998 Nov 9;252(1):190-4 PMID: 9813168
  52. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells.
    Exp Cell Res. 1998 Jun 15;241(2):414-25 PMID: 9637783
  53. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.
    Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 PMID: 9223322
  54. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls.
    FASEB J. 1999 Oct;13(13):1743-50 PMID: 10506577
  55. Inhibition of angiogenesis in vivo by interleukin 12.
    J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 PMID: 7538593
  56. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
    Biochem J. 1999 May 15;340 ( Pt 1):77-84 PMID: 10229661
  57. Angiogenesis and tumor metastasis.
    Annu Rev Med. 1998;49:407-24 PMID: 9509272
  58. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
    Invest New Drugs. 1997;15(1):39-48 PMID: 9195288
  59. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways.
    J Biol Chem. 1997 Oct 31;272(44):27509-12 PMID: 9346879
  60. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
    Cancer Res. 1995 Oct 15;55(20):4575-80 PMID: 7553632
  61. Novel forms of acidic fibroblast growth factor-1 are constitutively exported by beta tumor cell lines independent from conventional secretion and apoptosis.
    Angiogenesis. 1997;1(1):55-70 PMID: 14517394
  62. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.
    Cell. 1996 Dec 27;87(7):1171-80 PMID: 8980224
  63. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
    J Exp Med. 1995 Jul 1;182(1):155-62 PMID: 7540647
  64. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
    Science. 1999 Apr 30;284(5415):808-12 PMID: 10221914
  65. Establishing a link between oncogenes and tumor angiogenesis.
    Mol Med. 1998 May;4(5):286-95 PMID: 9642680
  66. Halting angiogenesis suppresses carcinoma cell invasion.
    Nat Med. 1997 Nov;3(11):1222-7 PMID: 9359696
  67. Angiostatin binds ATP synthase on the surface of human endothelial cells.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2811-6 PMID: 10077593
  68. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells.
    Proc Natl Acad Sci U S A. 1995 May 9;92(10):4606-10 PMID: 7538678
  69. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.
    Cancer Res. 1987 Oct 1;47(19):5155-61 PMID: 2441862
  70. Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments.
    Prog Mol Subcell Biol. 1998;20:161-76 PMID: 9928530
  71. The implications of angiogenesis on tumor invasiveness.
    Angiogenesis. 1998;2(1):21-3 PMID: 14517371
  72. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function.
    Cancer Res. 1999 Apr 1;59(7):1592-8 PMID: 10197634
  73. Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.
    Invest New Drugs. 1997;15(1):15-28 PMID: 9195286
  74. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma.
    Br J Cancer. 1998 Mar;77(6):897-902 PMID: 9528831
  75. Angiogenesis: a dynamic balance of stimulators and inhibitors.
    Thromb Haemost. 1997 Jul;78(1):672-7 PMID: 9198237
  76. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells.
    J Vasc Res. 1999 Jan-Feb;36(1):28-34 PMID: 10050071
  77. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src.
    J Biol Chem. 1998 Jan 9;273(2):1052-7 PMID: 9422768
Article Info
Journal
Journal of neuro-oncology
Abbr.
J Neurooncol
ISSN
0167-594X
DOI
10.1023/a:1006414621286
Published
2000-00-00
Pages
63-70
Language
English
Region
United States
NLM ID
8309335
Subset
IM
External Links
PubMed source DOI: 10.1023/a:1006414621286 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2